ReviewWorld journal of gastroenterology2019
Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression.
Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis.Digestive diseases and sciences · 2023Pooled it
- Seroprevalence and Early Indicators of HBV and HCV Co-infection Among Newly Diagnosed HIV Patients: A Cross-Sectional Study from India.AIDS and behavior · 2026Article
- Predictive value of serum S100A8/A9 for liver dysfunction in pregnant women with chronic hepatitis B.Virology journal · 2026Article
- Liver disease in people living with HIV infection: a changing landscape.Nature reviews. Gastroenterology & hepatology · 2026Review
- Active and resolved HCV infections among people with new HIV-1 diagnoses in Germany, 2009-2019.BMC infectious diseases · 2025Article
- HBsAg loss in HIV/HBV coinfected patients: Hepatitis B cure insights and implications.Infectious diseases & immunity · 2025Review
- Drug induced liver injury in HIV patients on dolutegravir based antiretroviral therapy regimens in Wolaita Sodo comprehensive specialized hospital.Scientific reports · 2025Article
- Hepatitis B virus exposure among adolescents living with HIV: a cross-sectional study of samples referred to the national viral load and early infant diagnosis reference laboratory in Uganda.BMC infectious diseases · 2025Article
- Co-infection with hepatitis B and human immunodeficiency virus: epidemiology, pathogenesis, and treatment.Infectious diseases & immunity · 2025Review
- Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data.Scientific reports · 2024Article
- YAP mediates HIV-related liver fibrosis.JHEP reports : innovation in hepatology · 2024Article
- Plasma proteomic profiles of patients with HIV infection and coinfection with hepatitis B/C virus undergoing anti‑retroviral therapy.Biomedical reports · 2024Article
- Association of serum lipid profile with liver fibrosis in HCV‑coinfected HIV patients on suppressive anti‑retroviral therapy.Biomedical reports · 2024Article
- Renal Manifestations of Chronic Hepatitis C: A Review.Journal of clinical medicine · 2024Review
- Impact of the 2008 economic crisis on the burden of hepatitis B and C diseases in Southern European countries.BMC public health · 2024Article
- Prevalence of occult hepatitis B infection among treatment-naive persons living with HIV in Ghana.PloS one · 2024Article
- [Delta hepatitis in Africa: epidemiological and clinical particularities].Medecine tropicale et sante internationale · 2023Review
- HIV-HBV Coinfection-Current Challenges for Virologic Monitoring.Biomedicines · 2023Review
- Modeling SARS-CoV-2 and HBV co-dynamics with optimal control.Physica A · 2023Article
- Serum protein biomarkers for HCC risk prediction in HIV/HBV co-infected people: a clinical proteomic study using mass spectrometry.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatotropic viruses induced hepatitis progresses much faster and causes more liver- related health problems in people co-infected with human immunodeficiency virus (HIV). Although treatment with antiretroviral therapy has extended the life expectancy of people with HIV, liver disease induced by hepatitis B virus (HBV) and hepatitis C virus (HCV) causes significant numbers of non-acquired immune deficiency syndrome (AIDS)-related deaths in co-infected patients. In recent years, new insights into the mechanisms of accelerated fibrosis and liver disease progression in HIV/HCV and HIV/HBV co-infections have been reported. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease in HIV-HCV/HBV co-infection in the era of direct acting antivirals (DAA) and antiretroviral therapy (ART). We also review the novel therapeutics for management of HIV/HCV and HIV/HBV co-infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.